{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:55:41Z","timestamp":1787316941010,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"am","delay-in-days":345,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ijcard.2022.12.051","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T02:16:27Z","timestamp":1672366587000},"page":"110-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Not baseline but time-dependent erythropoiesis-stimulating agent responsiveness predicts cardiovascular disease in hemodialysis patients receiving epoetin beta pegol: A multicenter prospective PARAMOUNT-HD Study"],"prefix":"10.1016","volume":"375","author":[{"given":"Hideki","family":"Fujii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kuragano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Joki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Tsuruya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2022.12.051_bb0005","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1681\/ASN.2019060574","article-title":"Incident hospitalization with major cardiovascular diseases and subsequent risk of ESKD: implications for Cardiorenal major cardiovascular diseases and subsequent risk of ESKD: implications for Cardiorenal syndrome","volume":"31","author":"Ishigami","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ijcard.2022.12.051_bb0010","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ahj.2007.10.031","article-title":"Hemoglobin levels and coronary artery disease","volume":"155","author":"Chonchol","year":"2008","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2022.12.051_bb0015","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1161\/CIRCULATIONAHA.105.577577","article-title":"Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in chronic heart failure: outcomes and resource utilization (ANCHOR) study","volume":"113","author":"Go","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2022.12.051_bb0020","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2022.12.051_bb0025","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2022.12.051_bb0030","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"CREATE Investigators: normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Dr\u00fceke","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2022.12.051_bb0035","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"TREAT Investigators: a trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2022.12.051_bb0040","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ki.2008.295","article-title":"Secondary analysis of the CHOIR trial epoetin\u2013alpha dose and achieved hemoglobin outcomes","volume":"74","author":"Szczech","year":"2008","journal-title":"Kidney Int."},{"key":"10.1016\/j.ijcard.2022.12.051_bb0045","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10157-018-1632-9","article-title":"Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan","volume":"23","author":"Tanaka","year":"2019","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.ijcard.2022.12.051_bb0050","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1056\/NEJMoa1005109","article-title":"Trial to reduce cardiovascular events with Aranesp therapy (TREAT) Investigators: Erythropoietic response and outcomes in kidney disease and type 2 diabetes","volume":"363","author":"Solomon","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2022.12.051_bb0055","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.ajkd.2011.07.014","article-title":"Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the Dialysis registry in Japan","volume":"59","author":"Fukuma","year":"2012","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ijcard.2022.12.051_bb0060","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000523947","article-title":"Resistance to Erythropiesis-stimulating agents among patients on hemodialysis is typically transient","volume":"53","author":"Goodkin","year":"2022","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.ijcard.2022.12.051_bb0070","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10157-012-0659-6","article-title":"The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study","volume":"17","author":"Ishigami","year":"2013","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.ijcard.2022.12.051_bb0075","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1440-1797.2007.00810.x","article-title":"Erythropoiesis-stimulating agent hyporesponsiveness","volume":"12","author":"Johnson","year":"2007","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.ijcard.2022.12.051_bb0080","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1159\/000516901","article-title":"Managing Anemia across the stages of kidney Disease in those Hyporesponsive to erythropoiesis-stimulating agents","volume":"52","author":"Weir","year":"2021","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.ijcard.2022.12.051_bb0085","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/ndt\/gfu345","article-title":"High-volume online haemodiafiltration improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study","volume":"30","author":"Panichi","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ijcard.2022.12.051_bb0090","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s40620-020-00709-0","article-title":"Mixed hemodiafiltration reduces erythropoiesis stimulating agents requirement in dialysis patients: a prospective randomized study","volume":"33","author":"Pedrini","year":"2020","journal-title":"J Nephrol"},{"key":"10.1016\/j.ijcard.2022.12.051_bb0095","article-title":"Improving global outcomes (KDIGO) anemia work group: KDIGO clinical practice guideline for Anemia in chronic kidney Disease","volume":"279\u2013335","author":"Kidney Disease","year":"2012","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.ijcard.2022.12.051_bb0100","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s41100-017-0114-y","article-title":"2015 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease","volume":"3","author":"Yamamoto","year":"2017","journal-title":"Renal Replacement Therapy"},{"issue":"Suppl. 8","key":"10.1016\/j.ijcard.2022.12.051_bb0105","first-page":"viii7","article-title":"The cardio-renal anaemia syndrome: does it exist?","volume":"18","author":"Silverberg","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ijcard.2022.12.051_bb0110","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ijcard.2011.07.045","article-title":"Erythropoietin resistance contributes to anaemia in chronic heart failure and relates to aberrant JAK-STAT signal transduction","volume":"164","author":"Okonko","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2022.12.051_bb0115","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jacc.2017.12.027","article-title":"The burden of Iron deficiency in heart failure: therapeutic approach","volume":"71","author":"Rocha","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2022.12.051_bb0120","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.030099","article-title":"Anemia and iron deficiency in heart failure: current concepts and emerging therapies","volume":"138","author":"Ananda","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2022.12.051_bb0125","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ejhf.1154","article-title":"Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function","volume":"20","author":"Hoes","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2022.12.051_bb0130","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1161\/CIRCRESAHA.119.316453","article-title":"Iron-deficiency and estrogen are associated with ischemic stroke by up-regulating transferrin to induce hypercoagulability","volume":"127","author":"Tang","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcard.2022.12.051_bb0135","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s10157-020-02005-4","volume":"25","author":"Tsuruya","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.ijcard.2022.12.051_bb0140","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.2215\/CJN.01380219","article-title":"Cardiovascular safety and all-cause mortality of methoxy polyethylene glycol-epoetin beta and other erythropoiesis-stimulating agents in anemia of CKD: a randomized noninferiority trial","volume":"14","author":"Locatelli","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ijcard.2022.12.051_bb0145","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1681\/ASN.2018101007","article-title":"Types of erythropoietin-stimulating agents and mortality among patients undergoing hemodialysis","volume":"30","author":"Sakaguchi","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ijcard.2022.12.051_bb0150","first-page":"CD009904","article-title":"Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease","volume":"8","author":"Saglimbene","year":"2017","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527322019763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527322019763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:59:16Z","timestamp":1759093156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527322019763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":29,"alternative-id":["S0167527322019763"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2022.12.051","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Not baseline but time-dependent erythropoiesis-stimulating agent responsiveness predicts cardiovascular disease in hemodialysis patients receiving epoetin beta pegol: A multicenter prospective PARAMOUNT-HD Study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2022.12.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}